• Xue-Fei Cai, Juan Chen, Jie- Li Hu, Quan-Xin Long, Hai-Jun Deng, Ping Liu, Kai Fan, Pu Liao, Bei-Zhong Liu, Gui-Cheng Wu, Yao-Kai Chen, Zhi-Jie Li, Kun Wang, Xiao-Li Zhang, Wen-Guang Tian, Jiang-Lin Xiang, Hong-Xin Du, Jing Wang, Yuan Hu, Ni Tang, Yong Lin, Ji-Hua Ren, Lu-Yi Huang, Jie Wei, Chun-Yang Gan, Yan-Meng Chen, Qing-Zhu Gao, A-Mei Chen, Chang-Long He, Dao-Xin Wang, Peng Hu, Fa-Chun Zhou, Ai-Long Huang, and De-Qiang Wang.
• Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China.
• J. Infect. Dis. 2020 Jun 29; 222 (2): 189-193.

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus, causes severe pneumonia and has spread throughout the globe rapidly. The disease associated with SARS-CoV-2 infection is named coronavirus disease 2019 (COVID-19). To date, real-time reverse-transcription polymerase chain reaction (RT-PCR) is the only test able to confirm this infection. However, the accuracy of RT-PCR depends on several factors; variations in these factors might significantly lower the sensitivity of detection.MethodsIn this study, we developed a peptide-based luminescent immunoassay that detected immunoglobulin (Ig)G and IgM. The assay cutoff value was determined by evaluating the sera from healthy and infected patients for pathogens other than SARS-CoV-2.ResultsTo evaluate assay performance, we detected IgG and IgM in the sera from confirmed patients. The positive rate of IgG and IgM was 71.4% and 57.2%, respectively.ConclusionsTherefore, combining our immunoassay with real-time RT-PCR might enhance the diagnostic accuracy of COVID-19.© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

44 keywords...

hide…